Interaction between Non-Coding RNAs and Androgen Receptor with an Especial Focus on Prostate Cancer
- PMID: 34831421
 - PMCID: PMC8619311
 - DOI: 10.3390/cells10113198
 
Interaction between Non-Coding RNAs and Androgen Receptor with an Especial Focus on Prostate Cancer
Abstract
The androgen receptor (AR) is a member of the nuclear receptor superfamily and has three functional domains, namely the N-terminal, DNA binding, and C-terminal domain. The N-terminal domain harbors potent transactivation functions, whereas the C-terminal domain binds to androgens and antiandrogens used to treat prostate cancer. AR has genomic activity being DNA binding-dependent or through interaction with other DNA-bound transcription factors, as well as a number of non-genomic, non-canonical functions, such as the activation of the ERK, AKT, and MAPK pathways. A bulk of evidence indicates that non-coding RNAs have functional interactions with AR. This type of interaction is implicated in the pathogenesis of human malignancies, particularly prostate cancer. In the current review, we summarize the available data on the role of microRNAs, long non-coding RNAs, and circular RNAs on the expression of AR and modulation of AR signaling, as well as the effects of AR on their expression. Recognition of the complicated interaction between non-coding RNAs and AR has practical importance in the design of novel treatment options, as well as modulation of response to conventional therapeutics.
Keywords: androgen receptor; circular RNAs; lncRNA; miRNA; prostate cancer.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
              
              
              
              
                
                
                
 reduction or inhibition of, 
 increased levels of, 
 decreased levels of).
              
              
              
              
                
                
                
 increased levels of, 
 decreased levels of).
              
              
              
              
                
                
                
 reduction or inhibition of, 
 increased levels of, 
 decreased levels of).
              
              
              
              
                
                
                
 reduction or inhibition of, 
 increased levels of, 
 decreased levels of).
              
              
              
              
                
                
                
 reduction or inhibition of, 
 increased levels of, 
 decreased levels of).References
- 
    
- Lu N.Z., Wardell S.E., Burnstein K.L., DeFranco D., Fuller P., Giguère V., Hochberg R.B., McKay L., Renoir J.-M., Weigel N.L., et al. International Union of Pharmacology. LXV. The pharmacology and classification of the nuclear receptor superfamily: Glucocorticoid, mineralocorticoid, progesterone, and androgen receptors. Pharmacol. Rev. 2006;58:782–797. doi: 10.1124/pr.58.4.9. - DOI - PubMed
 
 
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
